Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Tenney

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Journal of Hepatology|March 26, 2008
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic responseCarl J Baldick, Betsy J Eggers, Jie Fang, et al.
Journal of Virology|February 3, 2007
Inhibition of hepatitis B virus polymerase by entecavirDavid R Langley, Ann W Walsh, Carl J Baldick, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeksMorris Sherman, Cihan Yurdaydin, Halis Simsek, et al.
Journal of Virology|May 1, 1996
The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic miceJ F Baskar, P P Smith, G Nilaver, et al.
Hepatology (Baltimore, Md.)|March 13, 2009
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyDaniel J Tenney, Ronald E Rose, Carl J Baldick, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2009
Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolatesJie Fang, Michael J Wichroski, Steven M Levine, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Entecavir resistance is rare in nucleoside naïve patients with hepatitis BRichard J Colonno, Ronald Rose, Carl J Baldick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in MelanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Hepatology (Baltimore, Md.)|January 6, 2010
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis BTing-Tsung Chang, Ching-Lung Lai, Seung Kew Yoon, et al.
International Journal of Cancer|August 6, 2022
A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumorsNamit Kumar, Simon Papillon-Cavanagh, Hao Tang, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|March 26, 2008
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic responseCarl J Baldick, Betsy J Eggers, Jie Fang, et al.
Journal of Virology|February 3, 2007
Inhibition of hepatitis B virus polymerase by entecavirDavid R Langley, Ann W Walsh, Carl J Baldick, et al.
Hepatology (Baltimore, Md.)|June 10, 2008
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeksMorris Sherman, Cihan Yurdaydin, Halis Simsek, et al.
Journal of Virology|May 1, 1996
The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic miceJ F Baskar, P P Smith, G Nilaver, et al.
Hepatology (Baltimore, Md.)|March 13, 2009
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyDaniel J Tenney, Ronald E Rose, Carl J Baldick, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2009
Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolatesJie Fang, Michael J Wichroski, Steven M Levine, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Entecavir resistance is rare in nucleoside naïve patients with hepatitis BRichard J Colonno, Ronald Rose, Carl J Baldick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in MelanomaKelsey R Monson, Robert Ferguson, Joanna E Handzlik, et al.
Hepatology (Baltimore, Md.)|January 6, 2010
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis BTing-Tsung Chang, Ching-Lung Lai, Seung Kew Yoon, et al.
International Journal of Cancer|August 6, 2022
A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumorsNamit Kumar, Simon Papillon-Cavanagh, Hao Tang, et al.
Pageof 6